Research & Development News
Results of a Survey of Parents' Perceptions of the Duration of their Child's ADHD Medication
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced results of a national survey where 60 percent of 121 mothers reported their 6 to 12 year old child's once-daily Attention Deficit Hyperactivity Disorder (ADHD) medication stopped working before 6 p.m. The survey findings report the perceptions of 500 parents of children with ADHD regarding the duration of effectiveness of their child's once-daily stimulant or non-stimulant ADHD medication and were presented yesterday at the 2007 Children and Adults with Attention-Deficit Hyperactivity Disorder (CHADD) Annual Conference. Web Site Helps Alleviate Stress Associated with Caring for Children with Diabetes During the Holiday
Holidays often induce stress, but caring for children with diabetes this time of year can mean an additional layer of pressure. Parents and caregivers can visit a webiste to participate in live Web chats with diabetes specialists for expert advice on how to best manage a child's diabetes during the holidays, find social support and receive a free download of the 'Diabetes Fit Food' booklet for tips on healthy eating. Computational modelling allows insights into cell membrane fusion
More than 25 Years of Archived Biomedical and Pharmacological Records Acessible in Electronic Format
Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that it has added EMBASE® Classic to the Dialog® (File 772) and DataStar® (EM73, EMXX) platforms, providing access to more than 25 years of archived life sciences data available for the first time in electronic format. EUR 5.2 million for Belgian drug research
EU project improves ability to predict outcome of HIV treatment
More Pharma News ...
Business & Industry
- Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries
- WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Novartis invests in early technical development capabilities for next-generation biotherapeutics
- FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
Research & Development
- National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy
- 2nd Annual Next Generation Pharmaceutical Cleanrooms Conference
- Shutting down backup genes leads to cancer remission in mice
- Bird's enzyme points toward novel therapies
- WHO strongly advises against antibody treatments for COVID-19 patients
- Mucosal antibodies in the airways protect against omicron infection
- Drug turns cancer gene into "eat me" flag for immune system
Conferences & Events
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
- SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
- SMi's 3rd Annual AI in Drug Discovery Conference
- SMi's 6th Annual Highly Potent Active Pharmaceutical Ingredients
Regulatory Affairs
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice